Brokers Offer Predictions for NovoCure Limited’s Q4 2025 Earnings (NASDAQ:NVCR)

NovoCure Limited (NASDAQ:NVCR) – Equities research analysts at Wedbush cut their Q4 2025 earnings per share estimates for shares of NovoCure in a report released on Wednesday, March 27th. Wedbush analyst D. Nierengarten now anticipates that the medical equipment provider will post earnings per share of ($0.36) for the quarter, down from their prior estimate of ($0.35). Wedbush has a “Neutral” rating and a $21.00 price target on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.73) per share. Wedbush also issued estimates for NovoCure’s FY2026 earnings at ($1.45) EPS and FY2027 earnings at ($1.38) EPS.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.08. The firm had revenue of $133.80 million during the quarter, compared to analyst estimates of $133.80 million. NovoCure had a negative return on equity of 51.63% and a negative net margin of 40.65%. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.36) earnings per share.

Several other analysts also recently weighed in on NVCR. Evercore ISI lifted their price target on shares of NovoCure from $14.00 to $15.00 and gave the company an “in-line” rating in a research note on Friday, February 23rd. HC Wainwright boosted their price objective on shares of NovoCure from $22.00 to $24.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of NovoCure from $15.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 19th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.13.

NovoCure Stock Performance

Shares of NASDAQ NVCR opened at $15.63 on Friday. The company has a debt-to-equity ratio of 1.57, a current ratio of 5.78 and a quick ratio of 5.56. NovoCure has a 1 year low of $10.87 and a 1 year high of $83.60. The firm has a 50-day simple moving average of $14.95 and a two-hundred day simple moving average of $14.46.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. US Bancorp DE raised its position in shares of NovoCure by 18.9% during the 1st quarter. US Bancorp DE now owns 2,857 shares of the medical equipment provider’s stock worth $237,000 after purchasing an additional 454 shares during the last quarter. Panagora Asset Management Inc. raised its position in shares of NovoCure by 280.8% during the 1st quarter. Panagora Asset Management Inc. now owns 12,702 shares of the medical equipment provider’s stock worth $1,052,000 after purchasing an additional 9,366 shares during the last quarter. BlackRock Inc. raised its position in shares of NovoCure by 0.6% during the 1st quarter. BlackRock Inc. now owns 6,732,513 shares of the medical equipment provider’s stock worth $557,787,000 after purchasing an additional 43,157 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of NovoCure by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 127,433 shares of the medical equipment provider’s stock worth $10,559,000 after purchasing an additional 2,534 shares during the last quarter. Finally, Blair William & Co. IL acquired a new position in shares of NovoCure during the 1st quarter worth about $572,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Insider Activity

In other news, EVP Frank X. Leonard sold 1,679 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $16.03, for a total transaction of $26,914.37. Following the sale, the executive vice president now directly owns 160,938 shares of the company’s stock, valued at $2,579,836.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Frank X. Leonard sold 1,679 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $16.03, for a total transaction of $26,914.37. Following the completion of the transaction, the executive vice president now directly owns 160,938 shares in the company, valued at $2,579,836.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Wilhelmus Cm Groenhuysen sold 2,107 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $16.03, for a total transaction of $33,775.21. Following the completion of the transaction, the chief operating officer now owns 252,452 shares of the company’s stock, valued at approximately $4,046,805.56. The disclosure for this sale can be found here. Insiders have sold 7,921 shares of company stock valued at $127,161 over the last ninety days. 5.67% of the stock is currently owned by insiders.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.